Stockreport

Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta  

MOMENTA PHARMACEUTICALS  (MNTA) 
Last momenta pharmaceuticals earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.momentapharma.com/investor-relations
PDF Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and n [Read more]